Cargando…
A rare case of synchronous multiple primary lung cancer with different responses to gefitinib
Differentiating multiple primary lung cancer (MPLC) from lung metastasis is important, and the pathology and gene mutations may be different between the tumors. A lung biopsy to differentiate lesions should be considered, especially when the response of different tumors to treatment is distinct.
Autores principales: | Liao, Che-Chi, Lin, Yu-Sen, Lin, Yu-Chao, Cheng, Chiao-Jen, Chen, Shuo-Chueh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596341/ https://www.ncbi.nlm.nih.gov/pubmed/33145160 http://dx.doi.org/10.1016/j.rmcr.2020.101270 |
Ejemplares similares
-
Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005) -
Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer
por: Wang, Hsian-Yu, et al.
Publicado: (2016) -
SUVmax and Tumor Size Predict Surgical Outcome of Synchronous Multiple Primary Lung Cancers
por: Hsu, Hsian-He, et al.
Publicado: (2016) -
Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015) -
Primary lung neoplasms presenting as multiple synchronous lung nodules
por: Ghosh, Subha, et al.
Publicado: (2020)